Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL403998 | 1.00 | USP2 (0.53) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Acetic Acid SCHEMBL8370700 | 1.00 | USP2 (0.53) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Acetic Acid SCHEMBL7572044 | 1.00 | USP2 (0.53) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Pyruvate SCHEMBL17296438 | 0.94 | USP2 (0.48) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Bicarbonate SCHEMBL20888 | 0.94 | USP2 (0.55) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL2227363 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL8586304 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL420278 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL1548302 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL22963142 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109631-A1 | SYNTHETIC DELIVERY SYSTEMS AND CONJUGATES THEREOF | MICRO CRISPR PVT. LTD. (IN) | 2025-05-30 | — | — | WO | claimed |
| EP-4519278-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | Amgen Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| CN-119431471-A | Synthesis method of trivalent GalNAc compound | 中国药科大学 | 2025-02-14 | — | — | CN | claimed |
| CN-118852276-A | Preparation method of L96 intermediate compound | 苏州富士莱医药股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118340917-A | PET/MR bimodal imaging probe based on magnetic ferric oxide nanoparticle | 江南大学附属医院 | 2024-07-16 | — | — | CN | claimed |
| CN-117384226-A | Synthesis process of GalNAc compound | 苏州盛诺维生物科技有限公司 | 2024-01-12 | — | — | CN | claimed |
| WO-2023215306-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | AMGEN INC. (US) | 2023-11-09 | — | — | WO | claimed |
| CN-113150046-A | Preparation method of N-acetyl-D-galactosamine | 安徽银丰药业股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-111196828-A | Synthetic method of selenium monosaccharide metabolic marker | 迈科若(苏州)医疗科技有限公司 | 2020-05-26 | — | — | CN | claimed |
| CN-122095089-A | Inhibitors of expression and/or function | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4744668-A2 | POLYNUCLEOTIDE CONSTRUCTS | Sirius Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260103705-A1 | COMPOSITION AND METHOD FOR INHIBITING ANGIOTENSINOGEN (AGT) PROTEIN EXPRESSION | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-04-16 | — | — | US | disclosed |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| EP-4534092-B1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-2231195-A2 | TARGETING LIPIDS | Alnylam Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2229186-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20090247608-A1 | Targeting Lipids | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009082607-A2 | TARGETING LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247608-A1 | Targeting Lipids | LY96, ABHD10, APOB | USP2 1419/4885SLCO1B1 1319/4885PAX8 4335/4885 |
| US-20260103705-A1 | COMPOSITION AND METHOD FOR INHIBITING ANGIOTENSINOGEN (AGT) PROTEIN EXPRESSION | AGT, IGF2BP2, IGF2BP1 | USP2 1940/4885SLCO1B1 665/4885PAX8 2722/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | USP2 4177/4885SLCO1B1 1978/4885PAX8 2857/4885 |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | USP2 3839/4885SLCO1B1 152/4885PAX8 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.